Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

Martin Bögemann; Neal D Shore; Matthew R Smith; Teuvo L J Tammela; Albertas Ulys; Egils Vjaters; Sergey Polyakov; Mindaugas Jievaltas; Murilo Luz; Boris Alekseev; Thierry Lebret; Martin Schostak; Frank Verholen; Marie-Aude Le Berre; Shankar Srinivasan; Jorge Ortiz; Ateesha F Mohamed; Toni Sarapohja; Karim Fizazi

doi:10.1016/j.eururo.2022.11.018

Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

Martin Bögemann (Corresponding Author)
, Neal D Shore
, Matthew R Smith
, Teuvo L J Tammela
, Albertas Ulys
, Egils Vjaters
, Sergey Polyakov
, Mindaugas Jievaltas
, Murilo Luz
, Boris Alekseev
, Thierry Lebret
, Martin Schostak
, Frank Verholen
, Marie-Aude Le Berre
, Shankar Srinivasan
, Jorge Ortiz
, Ateesha F Mohamed
, Toni Sarapohja
, Karim Fizazi

Research output: Contribution to journal › Erratum

1 Citation (Scopus)

Abstract

The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	e60
Number of pages	1
Journal	European Urology
Volume	83
Issue number	2
DOIs	https://doi.org/10.1016/j.eururo.2022.11.018 https://doi.org/10.1016/j.eururo.2022.11.018
Publication status	Published - Feb 2023
Externally published	Yes

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.sciencedirect.com/science/article/pii/S0302283822028378?via%3Dihub

Fingerprint

Dive into the research topics of 'Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))'. Together they form a unique fingerprint.

1 Citations
1 Article

Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
Bögemann, M. (Corresponding Author), Shore, N. D., Smith, M. R., Tammela, T. L. J., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Lebret, T., Schostak, M., Verholen, F., Le Berre, M. A., Srinivasan, S., Ortiz, J., Mohamed, A. F., Sarapohja, T. & Fizazi, K., Mar 2023, In: European Urology. 83, 3, p. 212-221 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
10 Citations (Scopus)

Cite this

Bögemann, M., Shore, N. D., Smith, M. R., Tammela, T. L. J., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Lebret, T., Schostak, M., Verholen, F., Le Berre, M.-A., Srinivasan, S., Ortiz, J., Mohamed, A. F., Sarapohja, T., & Fizazi, K. (2023). Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). European Urology, 83(2), e60. https://doi.org/10.1016/j.eururo.2022.11.018, https://doi.org/10.1016/j.eururo.2022.11.018

Bögemann, Martin ; Shore, Neal D ; Smith, Matthew R et al. / Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time : Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). In: European Urology. 2023 ; Vol. 83, No. 2. pp. e60.

@article{6c50d50a99634ae6bebaed672614a2f1,

title = "Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))",

abstract = "The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.",

author = "Martin B{\"o}gemann and Shore, \{Neal D\} and Smith, \{Matthew R\} and Tammela, \{Teuvo L J\} and Albertas Ulys and Egils Vjaters and Sergey Polyakov and Mindaugas Jievaltas and Murilo Luz and Boris Alekseev and Thierry Lebret and Martin Schostak and Frank Verholen and \{Le Berre\}, Marie-Aude and Shankar Srinivasan and Jorge Ortiz and Mohamed, \{Ateesha F\} and Toni Sarapohja and Karim Fizazi",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2023",

month = feb,

doi = "10.1016/j.eururo.2022.11.018",

language = "English",

volume = "83",

pages = "e60",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

Bögemann, M, Shore, ND, Smith, MR, Tammela, TLJ, Ulys, A, Vjaters, E, Polyakov, S, Jievaltas, M, Luz, M, Alekseev, B, Lebret, T, Schostak, M, Verholen, F, Le Berre, M-A, Srinivasan, S, Ortiz, J, Mohamed, AF, Sarapohja, T & Fizazi, K 2023, 'Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))', European Urology, vol. 83, no. 2, pp. e60. https://doi.org/10.1016/j.eururo.2022.11.018, https://doi.org/10.1016/j.eururo.2022.11.018

Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). / Bögemann, Martin (Corresponding Author); Shore, Neal D; Smith, Matthew R et al.
In: European Urology, Vol. 83, No. 2, 02.2023, p. e60.

Research output: Contribution to journal › Erratum

TY - JOUR

T1 - Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time

T2 - Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

AU - Bögemann, Martin

AU - Shore, Neal D

AU - Smith, Matthew R

AU - Tammela, Teuvo L J

AU - Ulys, Albertas

AU - Vjaters, Egils

AU - Polyakov, Sergey

AU - Jievaltas, Mindaugas

AU - Luz, Murilo

AU - Alekseev, Boris

AU - Lebret, Thierry

AU - Schostak, Martin

AU - Verholen, Frank

AU - Le Berre, Marie-Aude

AU - Srinivasan, Shankar

AU - Ortiz, Jorge

AU - Mohamed, Ateesha F

AU - Sarapohja, Toni

AU - Fizazi, Karim

PY - 2023/2

Y1 - 2023/2

N2 - The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

AB - The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85145287074

U2 - 10.1016/j.eururo.2022.11.018

DO - 10.1016/j.eururo.2022.11.018

M3 - Erratum

C2 - 36526492

SN - 0302-2838

VL - 83

SP - e60

JO - European Urology

JF - European Urology

IS - 2

ER -

Bögemann M, Shore ND, Smith MR, Tammela TLJ, Ulys A, Vjaters E et al. Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). European Urology. 2023 Feb;83(2):e60. doi: 10.1016/j.eururo.2022.11.018, 10.1016/j.eururo.2022.11.018